Fluzone Quadrivalent (influenza vaccine) / Sanofi - LARVOL DELTA

Evaluation of Human Immune Responses Vaccination in Patients with Lymphoma (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Emory University | Trial completion date: Oct 2024 ➔ May 2026 | Trial primary completion date: Oct 2024 ➔ May 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Carlo Contreras | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Cutaneous Melanoma • Infectious Disease • Influenza • Melanoma • Oncology • Respiratory Diseases • Solid Tumor

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years (clinicaltrials.gov) - P4 | N=3988 | Terminated | Sponsor: Fatimah Dawood | Active, not recruiting ➔ Terminated; Insufficient funding.

IO biomarker • Trial termination • Infectious Disease • Influenza • Respiratory Diseases • CD4 • CD40LG • CD8 • GZMB • IFNG • IL17A • IL2 • IL2RA • IL4 • LAMP1 • TNFA

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (clinicaltrials.gov) - P1/2 | N=682 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Rush University Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Solid Tumor • Triple Negative Breast Cancer

Intradermal Influenza Vaccination (clinicaltrials.gov) - P1 | N=249 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

FLU-TW: The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Stanford University | Recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Rush University Medical Center

New P1 trial • Breast Cancer • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Solid Tumor • Triple Negative Breast Cancer

Intradermal Influenza Vaccination (clinicaltrials.gov) - P1 | N=249 | Not yet recruiting | Sponsor: Yale University

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

FLU-TW: The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Stanford University

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

IIV-LN: Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Stanford University | N=50 ➔ 0 | Trial completion date: Dec 2025 ➔ Nov 2023 | Recruiting ➔ Withdrawn | Trial primary completion date: Dec 2024 ➔ Nov 2023

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Infectious Disease • Influenza • Respiratory Diseases

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Carlo Contreras | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Cutaneous Melanoma • Infectious Disease • Influenza • Melanoma • Oncology • Respiratory Diseases • Solid Tumor • CD20 • FOXP3 • GZMB • NCAM1 • PD-1

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years (clinicaltrials.gov) - P4 | N=3988 | Active, not recruiting | Sponsor: Fatimah Dawood | Recruiting ➔ Active, not recruiting | N=16247 ➔ 3988 | Trial completion date: Sep 2024 ➔ Dec 2023 | Trial primary completion date: Jun 2024 ➔ Dec 2023

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults (clinicaltrials.gov) - P3 | N=2654 | Completed | Sponsor: Novavax | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases • SPR

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (clinicaltrials.gov) - P1/2 | N=683 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Emory University | Trial completion date: Oct 2022 ➔ Oct 2024 | Trial primary completion date: Oct 2022 ➔ Oct 2024

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (clinicaltrials.gov) - P1/2 | N=690 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (clinicaltrials.gov) - P1/2 | N=690 | Not yet recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company

New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases

Tfh Dysfunction in HIV and Aging (clinicaltrials.gov) - P4 | N=400 | Recruiting | Sponsor: University of Miami | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Sep 2023 ➔ Sep 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Influenza • Respiratory Diseases • CD4